Post-marketing surveillance study on the effectiveness and safety of molnupiravir in high-risk COVID-19 outpatients: a prospective case series study
Pharmacological Reports · 2025
DOI: 10.1007/s43440-025-00729-2 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Pharmacological Reports, 2025. Verfasst von Renato Ferreira-da-Silva und 15 weiteren Autor:innen. Beteiligte Einrichtung: Porto Pharmacovigilance Centre, Faculty of Medicine of the University of Porto, Porto, Portugal. renato.ivos@gmail.com. Hauptthemen laut MEDLINE: Product Surveillance, Postmarketing, COVID-19 Drug Treatment, Antiviral Agents, Hydroxylamines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidade do Porto.
Abstract (Originalsprache)
Background
Molnupiravir, approved for treating mild to moderate COVID-19 in adults, aims to reduce hospitalisation and mortality rates. Although it was withdrawn from the market after the present study was conducted, understanding its long-term effects remains pertinent. We aimed to assess the real-world effectiveness and safety of molnupiravir in high-risk COVID-19 outpatients.
Methods
This prospective, multicenter, noninterventional, postmarketing cohort study enrolled high-risk COVID-19 outpatients with mild to moderate COVID-19, eligible under national prescribing criteria, who initiated molnupiravir within five days of symptom onset and were ineligible for first-line antiviral therapy. Patients were consecutively enrolled from eight Portuguese study sites and monitored for three months. Effectiveness was assessed by all-cause mortality and hospitalisation through day 29. Safety was evaluated by the incidence, severity, and causality of adverse events (AE), coded using MedDRA terminology and assessed via the WHO-UMC system. Data were collected through structured patient questionnaires and electronic health records. Statistical analysis was descriptive; proportions were reported with 95% confidence intervals (CI), and comparisons between groups were performed using appropriate statistical tests.
Results
By day 29 post-treatment initiation, no deaths were reported (n = 0; 0%; 95%CI = [0,26]), and all patients were either at home or institutionalised, with favourable outcomes. Out of the 12 patients enrolled, eight (67%; 95%CI = [35,90]) reported at least one AE, with the median time to the first AE being five days (range 5–7 days). Half of the patients (n = 6; 95%CI = [21,79]) reported AE deemed possibly or probably related to molnupiravir, involving nausea (25%), dizziness (17%), bitter taste (17%), and headache (17%). These AE were more commonly observed in older individuals and those overweight, indicating a potential influence of these factors on AE occurrence.
Conclusions
Molnupiravir appears to show good safety and effectiveness, offering an alternative for high-risk COVID-19 outpatients ineligible for first-line therapy. Despite its market withdrawal, ongoing research into its long-term effects is crucial to potentially repurpose it for other viral infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Porto Pharmacovigilance Centre, Faculty of Medicine of the University of Porto, Porto, Portugal. renato.ivos@gmail.com.
- Department of Community Medicine, Information and Health Decision Sciences (MEDCIDS), Faculty of Medicine of the University of Porto, Porto, Portugal. renato.ivos@gmail.com.
- RISE-Health, Porto, Portugal. renato.ivos@gmail.com.
- Porto Pharmacovigilance Centre, Faculty of Medicine of the University of Porto, Porto, Portugal.
- Department of Community Medicine, Information and Health Decision Sciences (MEDCIDS), Faculty of Medicine of the University of Porto, Porto, Portugal.
- RISE-Health, Porto, Portugal.
Förderung
- Universidade do Porto
Zitieren
APA
Ferreira-da-Silva, R., Silva, L., Costa-Santos, C., Morato, M., Polónia, J. J., Ribeiro-Vaz, I., Pinto, M., Pereira, M., Figueira, I. M., Baptista, S., Farinha, H., Falcão, F., Mirco, A., Calixto, L., Melo, M., & ESOA-19 Research Team (2025). Post-marketing surveillance study on the effectiveness and safety of molnupiravir in high-risk COVID-19 outpatients: a prospective case series study. Pharmacological Reports. https://doi.org/10.1007/s43440-025-00729-2
Vancouver
Ferreira-da-Silva R, Silva L, Costa-Santos C, Morato M, Polónia JJ, Ribeiro-Vaz I, et al. Post-marketing surveillance study on the effectiveness and safety of molnupiravir in high-risk COVID-19 outpatients: a prospective case series study. Pharmacological Reports. 2025. doi:10.1007/s43440-025-00729-2
BibTeX
@article{FerreiradaSilva2025,
author = {Ferreira-da-Silva, Renato and Silva, Lurdes and Costa-Santos, Cristina and Morato, Manuela and Polónia, Jorge Junqueira and Ribeiro-Vaz, Inês and Pinto, Manuela and Pereira, Marta and Figueira, Inês Marques and Baptista, Sofia and Farinha, Helena and Falcão, Fátima and Mirco, Ana and Calixto, Liliana and Melo, Madalena and ESOA-19 Research Team, ESOA-19 Research Team},
title = {Post-marketing surveillance study on the effectiveness and safety of molnupiravir in high-risk COVID-19 outpatients: a prospective case series study},
journal = {Pharmacological Reports},
year = {2025},
doi = {10.1007/s43440-025-00729-2}
}
EUVIMED